<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalibj.2023.105197</article-id><article-id pub-id-type="publisher-id">OALibJ-125267</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  Extra-Renal Rhabdoid Tumor: A Rare Malignant Tumor in Child about Four Cases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Layla</surname><given-names>Tahiri Elousrouti</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Imane</surname><given-names>Gouzi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ilham</surname><given-names>Tadmouri</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sara</surname><given-names>Benmiloud</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Meryem</surname><given-names>Boubou</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Youssef</surname><given-names>Abouabdellah</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>Bennis</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Laila</surname><given-names>Chbani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hinde</surname><given-names>Elfatemi</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nawal</surname><given-names>Hammas</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Pathology, Hospital University Hassan II, Fez, Morocco</addr-line></aff><aff id="aff3"><addr-line>Department of Radiology, Hospital University Hassan II, Fez, Morocco</addr-line></aff><aff id="aff5"><addr-line>Department of Ophthalmology, Hospital University Hassan II, Fez, Morocco</addr-line></aff><aff id="aff2"><addr-line>Department of Pediatrics, Hospital University Hassan II, Fez, Morocco</addr-line></aff><aff id="aff6"><addr-line>Laboratory of Biomedical and Translational Research, Faculty of Medicine and Pharmacology, Sidi Mohamed Ben Abdellah University, Fez, Morocco</addr-line></aff><aff id="aff4"><addr-line>Department of Pediatrics Surgery, Hospital University Hassan II, Fez, Morocco</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>04</month><year>2023</year></pub-date><volume>10</volume><issue>05</issue><fpage>1</fpage><lpage>10</lpage><history><date date-type="received"><day>29,</day>	<month>April</month>	<year>2023</year></date><date date-type="rev-recd"><day>27,</day>	<month>May</month>	<year>2023</year>	</date><date date-type="accepted"><day>30,</day>	<month>May</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  The rhabdoid tumor is a rare and aggressive tumor of pediatric population. Their grouping within a single entity is recent, following the discovery of a bi-allelic inactivation of the HSNF5/INI1 tumor suppressor gene in tumor cells. The present study aims to highlight the different epidemiological, clinical, histopathological, and immunohistochemical, and genetic features of extra-renal rhabdoid tumors in children. We present a case series of extra-renal rhabdoid tumor (ERRT), recorded at the Department of Pathology of University Hospital Center of Hassan 2 of Fez, in Morocco. From 2014 to 2022, four cases of extra renal rhabdoid tumor have been recorded in our department, their ages ranged from 2 to 7 months, and they were all boys. The sites most affected were the soft tissues. The histological analysis of all patients’ specimens demonstrates the presence of rhabdoid cells. In the immunohistochemistry study, we noted a complete loss of INI-1 staining by tumor cells. However, the tumor cells have cytoplasmic positivity with a dot-like pattern for epithelial membrane antigen (EMA), CK AE1/AE3, and vimentin. Two of our patients were treated with chemotherapy, and 2 patients underwent surgery and then chemotherapy. The evolution was lethal in all cases. Rhabdoid tumor is a rare and aggressive tumor that occurs in children. It should be included in the differential diagnosis of rounds cells tumors of children and thought about in front of any aggressive isolated tumor. It is a challenging diagnosis for pathologists, especially with tiny biopsy material, or minor rhabdoid components.
 
</p></abstract><kwd-group><kwd>Rhabdoid Tumor</kwd><kwd> Extra-Renal</kwd><kwd> Immunohistochemistry</kwd><kwd> INI-1</kwd><kwd> SMARCB-1</kwd><kwd> Child</kwd><kwd> Diagnosis</kwd><kwd> Case Series</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The rhabdoid tumor (RT) is a rare and aggressive tumor in the pediatric population. It is characterized by a clinical polymorphism because of the different locations that they can affect [<xref ref-type="bibr" rid="scirp.125267-ref1">1</xref>] . Extrarenal rhabdoid tumor is rare, and it is most often confined to infants and children. Among fetal and neonatal rhabdoid tumors, the extrarenal rhabdoid tumor is more common than those in the kidney or brain [<xref ref-type="bibr" rid="scirp.125267-ref2">2</xref>] . A few cases of primary rhabdoid tumor occurring in extra-renal sites have been reported, particularly in the soft tissues [<xref ref-type="bibr" rid="scirp.125267-ref3">3</xref>] . Rhabdoid tumor was first identified, in 1978, by Beckwith and Palmer in the kidney as a sarcomatous variant of Wilms tumor [<xref ref-type="bibr" rid="scirp.125267-ref4">4</xref>] . Then, in 1981, Haas et al. classified it as a distinct histopathologic entity of kidney tumors [<xref ref-type="bibr" rid="scirp.125267-ref5">5</xref>] .</p><p>Their grouping within a single entity is recent, following the discovery of a bi-allelic inactivation of the tumor suppressor gene SMARCB1 (hSNF5, BAF47, INI1), revealed by a complete loss of nuclear staining of INI-1 [<xref ref-type="bibr" rid="scirp.125267-ref6">6</xref>] . So, the histomorphological characteristics of rhabdoid tumors, their immunoreactivity to epithelial markers and vimentin, and the INI-1 loss are important tools for diagnosis. Therapeutic management remains multidisciplinary in the absence of any pre-established consensus. The present study aims to highlight the different epidemiological, clinical, histopathological, immunohistochemical, and genetic features of extra-renal rhabdoid tumors in children.</p></sec><sec id="s2"><title>2. Methods</title><sec id="s2_1"><title>2.1. Patients Selection</title><p>This is a case series that was performed among four children with extra renal rhabdoid tumor, which was diagnosed at the department of Pathology of University Hospital Center of Hassan 2 of Fez in Morocco. Clinicopathological data were collected from patients’ request forms and the pathology department files. From 2014 to 2022, four cases of extra renal rhabdoid tumor have been recorded in our department; details of clinical observations are summarized in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s2_2"><title>2.2. Histopathological Analysis</title><p>The histological analysis has been performed on formalin-fixed and paraffin-embedded tissue sections, with hematoxylin-eosin-saffron staining.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinicopathologic characteristics of our patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Case 1</th><th align="center" valign="middle" >Case 2</th><th align="center" valign="middle" >Case 3</th><th align="center" valign="middle" >Case 4</th></tr></thead><tr><td align="center" valign="middle" >Age (month)</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" >Boy</td><td align="center" valign="middle" >Boy</td><td align="center" valign="middle" >Boy</td><td align="center" valign="middle" >Boy</td></tr><tr><td align="center" valign="middle" >Region</td><td align="center" valign="middle" >Head and neck (soft tissue)</td><td align="center" valign="middle" >Trunk (soft tissue)</td><td align="center" valign="middle" >Central nervous system (CNS)</td><td align="center" valign="middle" >Orbit (soft tissue)</td></tr><tr><td align="center" valign="middle" >Site</td><td align="center" valign="middle" >Forehead</td><td align="center" valign="middle" >Axillary</td><td align="center" valign="middle" >Vermis</td><td align="center" valign="middle" >Intra conical, retro-orbital</td></tr><tr><td align="center" valign="middle" >Pathological specimens</td><td align="center" valign="middle" >Excisional biopsy</td><td align="center" valign="middle" >Fine-needle aspiration then a biopsy</td><td align="center" valign="middle" >Surgical excision</td><td align="center" valign="middle" >Biopsy</td></tr><tr><td align="center" valign="middle" >Treatment</td><td align="center" valign="middle" >Surgery + chemotherapy</td><td align="center" valign="middle" >Chemotherapy</td><td align="center" valign="middle" >Surgery + chemotherapy</td><td align="center" valign="middle" >Chemotherapy</td></tr><tr><td align="center" valign="middle" >Evolution</td><td align="center" valign="middle" >Obstruction of the contralateral eye and nose</td><td align="center" valign="middle" >Lung and lymph nodes metastasis</td><td align="center" valign="middle" >Quadriventricular hydrocephalus</td><td align="center" valign="middle" >Local progression</td></tr><tr><td align="center" valign="middle" >Prognosis</td><td align="center" valign="middle" >Death</td><td align="center" valign="middle" >Death</td><td align="center" valign="middle" >Death</td><td align="center" valign="middle" >Death</td></tr></tbody></table></table-wrap></sec><sec id="s2_3"><title>2.3. Immunohistochemical Analysis</title><p>Immunohistochemical analysis was performed on a 4 &#181;m tissue section from formalin-fixed and paraffin-embedded blocks, using primary antibodies according to the manufacturer’s guidelines, with immunohistochemical stainers (Ventana Ventana BenchMark ULTRA). For all antibodies, positive and negative controls were performed, including the processing of normal tissue or tumor sections known to be positive. We have used the primary antibodies represented in <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec></sec><sec id="s3"><title>3. Results</title><p>In the following, we are going to present the clinical, radiological and pathological details of each of our patients.</p><sec id="s3_1"><title>3.1. Case 1</title><p>A 2-month-old boy was referred to the pediatric department with a rapidly expanding soft tissue mass on the frontal region; it was present at birth, increasing progressively in volume. The clinical examination revealed a conscious child with a frontal mass of 6 cm (<xref ref-type="fig" rid="fig1">Figure 1</xref>(a)). Computerized tomographic imaging objectified a lobed cutaneous and subcutaneous tissue formation on the right front, taking the product of contrast heterogeneously without bone involvement, suggesting firstly hemangioma (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a)). The systemic evaluation showed no metastatic disease. The child underwent an excisional biopsy of the lesion with frozen section analysis which was performed, coming back from a round cell tumor. Histological assessment of the resected specimen after fixation in formol 10%, showed skin tissue presenting in the dermis a round cell proliferation organized in sheets or nests separated by a fine capillary network and sometimes adopting an epithelial appearance (<xref ref-type="fig" rid="fig3">Figure 3</xref>(a)). The cells are medium to</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Details of antibodies used in our study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Antibody</th><th align="center" valign="middle" >Clone</th><th align="center" valign="middle" >Staining</th></tr></thead><tr><td align="center" valign="middle" >IN-1</td><td align="center" valign="middle" >BAF47/SNF5/25</td><td align="center" valign="middle" >Nuclear</td></tr><tr><td align="center" valign="middle" >Vimentin</td><td align="center" valign="middle" >V9</td><td align="center" valign="middle" >Cytoplasmic</td></tr><tr><td align="center" valign="middle" >CK</td><td align="center" valign="middle" >AE1/AE3</td><td align="center" valign="middle" >Cytoplasmic dot like</td></tr><tr><td align="center" valign="middle" >EMA</td><td align="center" valign="middle" >E29</td><td align="center" valign="middle" >Dot-like</td></tr><tr><td align="center" valign="middle" >Myogenin</td><td align="center" valign="middle" >LO26</td><td align="center" valign="middle" >Nuclear</td></tr></tbody></table></table-wrap><p>large, contained often abundant eosinophilic cytoplasm with prominent eosinophilic para-nuclear inclusions; their nucleus is large, eccentric, round or oval, with mott chromatin and a large nucleolus (<xref ref-type="fig" rid="fig3">Figure 3</xref>(b)). Immunohistochemically, the tumor cells showed globular cytoplasmic staining for epithelial markers (CKAE1/AE3 and EMA) and vimentin, and a loss of INI-1 nuclear staining (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The outcome was marked by the increasing size of the frontal mass and the appearance of another peri-auricular mass of 4 cm. In the light of all these clinical, histological, and immunohistochemical features, the diagnosis of “extra-renal rhabdoid tumor” was done and treatment with chemotherapy was started but the child died after 7 weeks.</p></sec><sec id="s3_2"><title>3.2. Case 2</title><p>A 7-month-old boy was admitted for the management of a left subclavicular mass evolving for 40 days. Clinical examination found a huge mass under the left clavicular, extending to the axillary region (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)). The CT scan showed a bulky left axillary tumor mass, with lobulated contours, heterogeneously enhanced extending to the cervical region and the proximal portion of the ipsilateral left arm with irregular borders, massively necrotic in the center and vascularized (<xref ref-type="fig" rid="fig2">Figure 2</xref>(b)). Fine needle aspiration was carried out, showing a cellular smear with individual cells and clusters of rhabdoid cells, and round cells with eosinophilic cytoplasmic inclusions (<xref ref-type="fig" rid="fig3">Figure 3</xref>(c)). Then, a biopsy was done showing</p><p>the presence of rhabdoid cells arranged in sheets, which are large with abundant cytoplasm and hyaline globular inclusions of intermediate filaments, and eccentric vesicular nuclei with large inclusion-like nucleoli (<xref ref-type="fig" rid="fig3">Figure 3</xref>(d)). On the immunohistochemistry staining, we noted a complete loss of INI-1 by tumor cells. However, the tumor cells have cytoplasmic positivity with a dot-like pattern for epithelial membrane antigen (EMA), CK AE1/AE3, and vimentin (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The patient was treated with neoadjuvant chemotherapy, however, he was entrusted at the request of his family and subsequently died at home.</p></sec><sec id="s3_3"><title>3.3. Case 3</title><p>A 4-month-old boy presented with a gradually increasing mass in the left eye for 2 weeks. Computed tomography revealed a left intra-conical retro-orbital tumor process responsible for proptosis with a right cerebellar lesion that may be related to a secondary localization (<xref ref-type="fig" rid="fig2">Figure 2</xref>(c)). We received a biopsy of the mass. The histological analysis and immunohistochemical staining showed the same results as others cases. This patient underwent immediate surgery and then adjuvant Chemotherapy. Subsequently, he installed a quadriventricular hydrocephalus and then died after 8 weeks.</p></sec><sec id="s3_4"><title>3.4. Case 4</title><p>A 2-month-old boy presented with a gradually increasing mass in the left eye for 2 weeks. Cerebral computed tomography revealed a vermian tissue process, spontaneously dense, heterogeneously enhanced, extended to the right cerebellar hemisphere, and compressing V4 anteriorly (<xref ref-type="fig" rid="fig2">Figure 2</xref>(d)). We received a biopsy of the mass. The histological analysis and immunohistochemical staining showed the same results as others cases. The patient was treated with neoadjuvant chemotherapy but the child died after 4 weeks.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Rhabdoid tumor was first identified, in 1978, by Beckwith and Palmer in the kidney as a sarcomatous variant of Wilms tumor [<xref ref-type="bibr" rid="scirp.125267-ref4">4</xref>] . Then, in 1981, Haas et al. classified it as a distinct histopathologic entity of kidney tumors. It was called “rhabdoid” originally to the resemblance of this tumor to rhabdomyosarcoma on light microscopic examination and the lack of immunohistochemical and ultrastructural rhabdomyoblastic features led to it being referred to as a “rhabdoid” tumor. Now the rhabdoid features are understood to be cytoplasmic globoid aggregates of keratin and vimentin intermediate filaments [<xref ref-type="bibr" rid="scirp.125267-ref5">5</xref>] . Extrarenal rhabdoid tumor (ERRT) was first reported in 1982 by Gonzalez Crussi et al. as “round-cell sarcomas” of infants and young children, in the liver and chest wall [<xref ref-type="bibr" rid="scirp.125267-ref7">7</xref>] . Then, it was described in central nervous system (brain and spinal cord) in 1987 by Biggs et al. [<xref ref-type="bibr" rid="scirp.125267-ref8">8</xref>] . Actually, the WHO book defines, morphologically, rhabdoid tumor as a tumor containing a population of “rhabdoid” cells which are large with abundant cytoplasm, perinuclear spherical inclusions, and eccentric vesicular nuclei with large inclusion-like nucleoli, and genetically, by a bi-allelic inactivation of the tumor suppressor gene SMARCB1 (previously named hSNF5, BAF47, and INI-1) located on chromosome 22q11.2, secondary to an inactivating mutations, deletions or duplications of exons, resulting in a stop codon. This is revealed immunohistochemically by a complete loss of nuclear staining of INI-1 [<xref ref-type="bibr" rid="scirp.125267-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.125267-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.125267-ref9">9</xref>] . Our four tumors described here shared, in spite of disparate sites, important similarities, all arose in young male infants, and all had rapid growth and were quite voluminous at the time of their detection. Which is comparable to literature data as follows, ERRT is exceedingly rare, develops mostly in children however cases have been reported from new born to teenagers and adults [<xref ref-type="bibr" rid="scirp.125267-ref1">1</xref>] . In an Irish study between 1986 and 2013, the authors found only 4 cases of extrarenal extracranial rhabdoid tumor (EERT) (neck, paravertebral, tongue, and pelvis) out of a total of 25 rhabdoid tumor cases all location included [<xref ref-type="bibr" rid="scirp.125267-ref10">10</xref>] . Atypical teratoid/rhabdoid tumor (AT/RT) accounts for 1.6% off all pediatric CNS tumors and for 10% of CNS tumors in children aged less than 1 year [<xref ref-type="bibr" rid="scirp.125267-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.125267-ref2">2</xref>] . Rhabdoid tumor of the genital organs and gastro-intestinal tract typically affects older patients (mean age: 63.4 years; age range: 41 - 84 years) [<xref ref-type="bibr" rid="scirp.125267-ref11">11</xref>] . The sex ratio male to female is of 1.2 to 1 [<xref ref-type="bibr" rid="scirp.125267-ref3">3</xref>] .</p><p>The imaging characteristics of extra-renal rhabdoid tumors are not yet to be determined. Recently, Garces-Inigo et al. demonstrated that these tumors have a tendency to be large and hypodense on CT, and show a heterogeneous hyperintensity on T2-weighted (W) magnetic resonance imaging (MRI) [<xref ref-type="bibr" rid="scirp.125267-ref12">12</xref>] .</p><p>Histologically, rhabdoid tumor is characterized by a sheet of uniform, large epithelioid cells with vesicular chromatin, prominent nucleoli, and eosinophilic cytoplasm. A subset of cells contains hyaline cytoplasmic “rhabdoid” inclusions as it was defined above. However, there is many variant growth pattern such as myxoid, spindle cell/fascicular, clear-cell pattern, undifferentiated round cells and storiform pattern. Because of this heterogeneous morphology, MRT must be differentiated from rhabdomyosarcoma, epithelioid sarcoma, Ewing sarcoma, anaplastic large-cell lymphoma, melanoma, medulloblastoma and choroid plexus carcinoma. To do the difference between these differential diagnoses, an immunostaining must be done using different antibodies that are summarized in <xref ref-type="table" rid="table3">Table 3</xref>. Immunohistochemically, rhabdoid tumor displays complete loss of nuclear staining of SMARCB1/INI1, and it stains to smooth muscle actin (SMA), to CKAE1-AE3 (cytokeratin), to epithelial membrane antigen (EMA) and vimentin. This loss of expression of SMARCB1 is not specific for MRTs and it is found in other rare tumors like epithelioid sarcoma, epithelioid malignant peripheral nerve sheath tumor, pediatric chordoma [<xref ref-type="bibr" rid="scirp.125267-ref6">6</xref>] . It has been reported that aberrant expression can be classified into three patterns; complete loss, mosaic expression and reduced expression [<xref ref-type="bibr" rid="scirp.125267-ref6">6</xref>] .</p><p>Regarding therapeutic options, there is no clear consensus; but complete surgical excision remains the treatment of choice whenever feasible, otherwise neoadjuvant or adjuvant chemotherapy often associated with radiation is done. Targeted therapy is under investigation, utilizing various epigenetic pathways including DNA and histone methylation, histone deacetylation, cell cycle arrest and antimitotic mechanisms. Extra-renal MRT demonstrates a rapidly progressive evolution, with metastasis occurring in most patients from 2 to 15 months after diagnosis. It has a dismal prognosis, independent of localization. Disseminated disease to the lungs, lymph nodes, and liver at the time of diagnosis is reported. Death occurs in 80% to 90% of cases after an average period of 5.5 months [<xref ref-type="bibr" rid="scirp.125267-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.125267-ref10">10</xref>] .</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Differential diagnosis of rhabdoid tumor</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >INI-1</th><th align="center" valign="middle" >CK</th><th align="center" valign="middle" >EMA</th><th align="center" valign="middle" >VIM</th><th align="center" valign="middle" >MYOGENIN</th><th align="center" valign="middle" >CD99</th><th align="center" valign="middle" >CD30</th><th align="center" valign="middle" >HMB45</th><th align="center" valign="middle" >NSE</th></tr></thead><tr><td align="center" valign="middle" >Rhabdoid tumor</td><td align="center" valign="middle" >Loss</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td></tr><tr><td align="center" valign="middle" >Rhabdomyosarcoma</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td></tr><tr><td align="center" valign="middle" >Epithelioid sarcoma</td><td align="center" valign="middle" >Loss</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td></tr><tr><td align="center" valign="middle" >PNET/ewing sarcoma</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >+++</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td></tr><tr><td align="center" valign="middle" >Melanoma</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td></tr><tr><td align="center" valign="middle" >medulloblastoma</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >choroid plexus carcinoma</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td></tr><tr><td align="center" valign="middle" >Anaplastic large-cell lymphoma</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >−</td></tr></tbody></table></table-wrap></sec><sec id="s5"><title>5. Conclusion</title><p>Rhabdoid tumor is a rare and aggressive tumor that occurs in children. It should be included in the differential diagnosis of rounds cells tumors of children and thought about in front of any aggressive isolated tumor. The loss of the nuclear staining of INI-1 represents the key to the positive diagnosis in front of rhabdoid morphology. It is a challenging diagnosis for pathologists, especially with tiny biopsy material, or minor rhabdoid components. Despite advances in pediatric oncology, malignant rhabdoid tumors highlight difficulties in therapeutic decisions. We need a large comparative study to open perspectives for new targeted therapies aimed at controlling the inactivation of the SMARCB1 tumor suppressor gene and possibly propose prenatal diagnosis via cytogenetic study.</p></sec><sec id="s6"><title>Ethical Approval</title><p>As a retrospective study, and since Ethics Approval is not applicable due to de-identification of data, it is not required in our institution.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>All authors declare that they have no competing interest.</p></sec><sec id="s8"><title>Cite this paper</title><p>Tahiri Elousrouti, L., Gouzi, I., Tadmouri, I., Benmiloud, S., Boubou, M., Abouabdellah, Y., Bennis, A., Chbani, L., Elfatemi, H. and Hammas, N. (2023) Extra-Renal Rhabdoid Tumor: A Rare Malignant Tumor in Child about Four Cases. Open Access Library Journal, 10: e10197. https://doi.org/10.4236/oalib.1110197</p></sec></body><back><ref-list><title>References</title><ref id="scirp.125267-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Heck, J.E., Lombardi, C.A., Cockburn, M., Meyers, T.J., Wilhelm, M. and Ritz, B. (2013) Epidemiology of Rhabdoid Tumors of Early Childhood. Pediatric Blood &amp; Cancer, 60, 77-81. https://doi.org/10.1002/pbc.24141</mixed-citation></ref><ref id="scirp.125267-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">IARC (2020) Publication of the WHO Classification of Tumours, 5th Edition, Volume 3: Soft Tissue and Bone Tumours. IARC Press, Lyon.</mixed-citation></ref><ref id="scirp.125267-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fanburg-Smith, J.C., Hengge, M., Hengge, U.R., Smith, J.S.C. and Miettinen, M. (1998) Extrarenal Rhabdoid Tumors of Soft Tissue: A Clinicopathologic and Immunohistochemical Study of 18 Cases. Annals of Diagnostic Pathology, 2, 351-362.  
https://doi.org/10.1016/S1092-9134(98)80038-5</mixed-citation></ref><ref id="scirp.125267-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Beckwith, J.B. and Palmer, N.F. (1978) Histopathology and Prognosis of Wilms Tumor Results from the First National Wilms’ Tumor Study. Cancer, 41, 1937-1948.  
https://doi.org/10.1002/1097-0142(197805)41:5&lt;1937::AID-CNCR2820410538&gt;3.0.CO;2-U</mixed-citation></ref><ref id="scirp.125267-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Haas, J.E., Palmer, N.F., Weinberg, A.G. and Beckwith, J.B. (1981) Ultrastructure of Malignant Rhabdoid Tumor of the Kidney. A Distinctive Renal Tumor of Children. Human Pathology, 12, 646-657. https://doi.org/10.1016/S0046-8177(81)80050-0</mixed-citation></ref><ref id="scirp.125267-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kohashi, K. and Oda, Y. (2017) Oncogenic Roles of SMARCB1/INI1 and Its Deficient Tumors. Cancer Science, 108, 547-552. https://doi.org/10.1111/cas.13173</mixed-citation></ref><ref id="scirp.125267-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gonzalez-Crussi, F., Goldschmidt, R.A., Hsueh, W. and Trujillo, Y.P. (1982) Infantile Sarcoma with Intracytoplasmic Filamentous Inclusions: Distinctive Tumor of Possible Histiocytic Origin. Cancer, 49, 2365-2375.  
https://doi.org/10.1002/1097-0142(19820601)49:11&lt;2365::AID-CNCR2820491125&gt;3.0.CO;2-I</mixed-citation></ref><ref id="scirp.125267-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Biggs, P.J., Garen, P.D., Powers, J.M. and Garvin, J.J. (1987) Malignant Rhabdoid Tumor of the Central Nervous System. Human Pathology, 18, 332-337.  
https://doi.org/10.1016/S0046-8177(87)80161-2</mixed-citation></ref><ref id="scirp.125267-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Pawel, B.R. (2018) SMARCB1-Deficient Tumors of Childhood: A Practical Guide. Pediatric and Developmental Pathology, 21, 6-28.  
https://doi.org/10.1177/1093526617749671</mixed-citation></ref><ref id="scirp.125267-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Uwineza, A., et al. (2014) Rhabdoid Tumor: The Irish Experience 1986-2013. Cancer Genetics, 207, 398-402. https://doi.org/10.1016/j.cancergen.2014.05.015</mixed-citation></ref><ref id="scirp.125267-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Arafah, M.A. and Aljuboury, M.I. (2011) Primary Vulval Rhabdoid Tumor in an Adult: A Case Report, Immunohistochemical Profile and Literature Review. Case Reports in Medicine, 2011, Article ID: 162709. https://doi.org/10.1155/2011/162709</mixed-citation></ref><ref id="scirp.125267-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Garcés-I&amp;ntilde;igo, E.F., Leung, R., Sebire, N.J. and McHugh, K. (2009) Extrarenal Rhabdoid Tumours outside the Central Nervous System in Infancy. Pediatric Radiology, 39, 817-822. https://doi.org/10.1007/s00247-009-1288-4</mixed-citation></ref></ref-list></back></article>